{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:29:08Z","timestamp":1793039348654,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jneuroim.2021.577586","type":"journal-article","created":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T12:30:46Z","timestamp":1619613046000},"page":"577586","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review"],"prefix":"10.1016","volume":"356","author":[{"given":"Alessandro","family":"Dinoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Cheli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Bratina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Manganotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2021.577586_bb0005","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0010","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1474-4422(18)30244-8","article-title":"Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis","volume":"17","author":"Armangue","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0015","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jamaneurol.2016.2588","article-title":"Bortezomib treatment for patients with anti- N -methyl- d -aspartate receptor encephalitis","volume":"73","author":"Behrendt","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pediatrneurol.2019.09.004","article-title":"Bortezomib-responsive refractory anti-N-methyl-D-aspartate receptor encephalitis","volume":"103","author":"Cordani","year":"2020","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/ana.21050","article-title":"Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma","volume":"61","author":"Dalmau","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0030","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1212\/WNL.0b013e31822cfc6b","article-title":"Analysis of relapses in anti-NMDAR encephalitis","volume":"77","author":"Gabilondo","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577586_bb0035","doi-asserted-by":"crossref","first-page":"577565","DOI":"10.1016\/j.jneuroim.2021.577565","article-title":"Refractory NMDA-receptor encephalitis in a teenager: a novel use of Bortezomib","volume":"355","author":"Govil-Dalela","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0045","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1093\/brain\/awq113","article-title":"N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes","volume":"133","author":"Irani","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2021.577586_bb0050","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/cancers12020265","article-title":"Proteasome inhibitors for the treatment of multiple myeloma","volume":"12","author":"Ito","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jneuroim.2021.577586_bb0055","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/ene.13759","article-title":"Plasma cell depletion with bortezomib in the treatment of refractory N-methyl-d-aspartate (NMDA) receptor antibody encephalitis. Rational developments in neuroimmunological treatment","volume":"25","author":"Keddie","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0060","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1111\/imj.15118","article-title":"Bortezomib for the treatment of refractory anti-N-methyl-d-aspartate receptor encephalitis","volume":"50","author":"Kim","year":"2020","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0065","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1007\/s00415-020-09988-w","article-title":"Refractory anti-NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review","volume":"267","author":"Lazzarin","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0070","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ana.25421","article-title":"Development of the clinical assessment scale in autoimmune encephalitis","volume":"85","author":"Lim","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0075","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ana.25173","article-title":"N-methyl-D-aspartate receptor antibody production from germinal center reactions: therapeutic implications","volume":"83","author":"Makuch","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0080","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e318228c136","article-title":"Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis","volume":"77","author":"Martinez-Hernandez","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577586_bb0085","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcrc.2016.09.016","article-title":"Extra\u2013central nervous system target for assessment and treatment in refractory anti\u2013N-methyl-D-aspartate receptor encephalitis","volume":"37","author":"Nauen","year":"2017","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.jneuroim.2021.577586_bb0090","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1212\/WNL.0000000000003545","article-title":"The trouble with plasma cells","volume":"88","author":"R\u00fcegg","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577586_bb0095","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/WNL.0000000000003536","article-title":"Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis","volume":"88","author":"Scheibe","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2021.577586_bb0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00415-019-09585-6","article-title":"Daratumumab treatment for therapy-refractory anti-CASPR2 encephalitis","volume":"267","author":"Scheibe","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.clineuro.2018.06.005","article-title":"Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis","volume":"172","author":"Schroeder","year":"2018","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0110","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/acn3.557","article-title":"Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis","volume":"5","author":"Shin","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0115","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1093\/ajhp\/zxaa415","article-title":"Bortezomib for treatment of anti-NMDA receptor encephalitis in a pediatric patient refractory to conventional therapy","volume":"78","author":"Simmons","year":"2021","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jneuroim.2017.08.011","article-title":"Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis","volume":"312","author":"Sveinsson","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0125","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000353982","article-title":"Immunopathological significance of ovarian teratoma in patients with anti-N-methyl-D-aspartate receptor encephalitis","volume":"71","author":"Tabata","year":"2014","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0130","series-title":"Late-Onset Anti \u2013 NMDA Receptor Encephalitis","author":"Titulaer","year":"2013"},{"key":"10.1016\/j.jneuroim.2021.577586_bb0135","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2020.00188","article-title":"Early bortezomib therapy for refractory anti-NMDA receptor encephalitis","volume":"11","author":"Turnbull","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577527","article-title":"Efficacy and safety of bortezomib in rituximab-resistant anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis as well as the clinical characteristics: an observational study","volume":"354","author":"Wang","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13063-020-04516-7","article-title":"Generate-boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis","volume":"21","author":"Wickel","year":"2020","journal-title":"Trials"},{"key":"10.1016\/j.jneuroim.2021.577586_bb0155","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","article-title":"Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder","volume":"74","author":"Zhang","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jneuroim.2021.577586_bb0160","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/cns.13078","article-title":"The short-term efficacy of combined treatments targeting B cell and plasma cell in severe and refractory anti-N-methyl-D-aspartate receptor encephalitis: two case reports","volume":"25","author":"Zhang","year":"2019","journal-title":"CNS Neurosci. Ther."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821001132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572821001132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:39:08Z","timestamp":1759048748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572821001132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":32,"alternative-id":["S0165572821001132"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577586","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bortezomib in anti-N-Methyl-d-Aspartate-Receptor (NMDA-R) encephalitis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577586","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577586"}}